HCRU and costs among patients with schizophrenia switching from oral risperidone/paliperidone to once-monthly paliperidone palmitate: A VHA claims analysis

by | Apr 14, 2020 | Mental Health, Neurological, Publication

Abstract Authors: Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Richa Bashyal Background: Schizophrenia is associated with high health care resource utilization and treatment costs. Objective: This study compared treatment patterns, health care resource...

Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among VHA patients with schizophrenia with at least one prior hospitalization

by | Oct 17, 2019 | Mental Health, Neurological, Publication

Abstract Authors: Antoine El Khoury, Charmi Patel, Ahong Huang, Li Wang, Richa Bashyal Objective: To address gaps in the literature on healthcare resource utilization (HRU) and costs among patients with schizophrenia and prior hospitalization who transition from oral...

Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long‐acting injectable vs oral antipsychotics

by | May 20, 2019 | Mental Health, Neurological, Publication

Abstract Authors: Shah A, Xie L, Kariburyo F, Zhang Q, Gore M Introduction: Long-acting injectable (LAI) antipsychotic use may reduce healthcare resource utilization compared with oral antipsychotic use by improving adherence and reducing dosing frequency. Our goal...